Affordable Access

Publisher Website

PLGA nanoparticle formulations of risperidone: preparation and neuropharmacological evaluation

Authors
Journal
Nanomedicine Nanotechnology Biology and Medicine
1549-9634
Publisher
Elsevier
Publication Date
Volume
5
Issue
3
Identifiers
DOI: 10.1016/j.nano.2008.12.003
Keywords
  • Atomic Force Microscopy
  • Psychopharmacology
  • Photon Correlation Spectroscopy
  • Poloxamer 407
  • Poly(D
  • L-Lactide-Co-Glycolide) Nanoparticles
  • Risperidone
Disciplines
  • Design
  • Physics

Abstract

Abstract The aim of this work was to develop extended-release poly( d, l-lactide-co-glycolide) (PLGA) nanoparticles of risperidone and thermal-responsive in situ gel containing risperidone nanoparticles for parenteral (subcutaneous) delivery and to reduce the dose-dependent extrapyramidal side effects of risperidone. PLGA nanoparticles of risperidone were designed by nanoprecipitation method using polymeric stabilizer (Poloxamer 407). The prepared nanoparticles were characterized for particle size by photon correlation spectroscopy and atomic force microscopy. Poloxamer 407–based in situ gel containing PLGA nanoparticles of risperidone was prepared by modified cold method to control the initial rapid release from the nanoparticles. The in vivo efficacy (antipsychotic effect) of prepared formulations (nanoparticles and in situ gel containing nanoparticles) was studied by administering them subcutaneously to mice. Extrapyramidal side effects of the formulations were also studied. The particle size of the prepared nanoparticles ranged between 85 and 219 nm. About 89% to 95% drug encapsulation efficiency was achieved when risperidone was loaded at 1.7% to 8.3% by weight of the polymer. During in vivo studies prepared risperidone formulations showed an antipsychotic effect that was significantly prolonged over that of risperidone solution for up to 72 hours with fewer extrapyramidal side effects. The prolonged effect of risperidone was obtained from the risperidone formulations administered subcutaneously, and this may improve the treatment of psychotic disorders by dose reduction. From the Clinical Editor The development of extended-release poly( d, l-lactide-co-glycolide) (PLGA) nanoparticles of risperidone is reported in this paper, along with the development of thermal-responsive in situ gel containing risperidone nanoparticles for parenteral (subcutaneous) delivery and to reduce the dose-dependent extrapyramidal side effects. In vivo studies showed a significantly prolonged antipsychotic effect with fewer extrapyramidal side effects.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

[Preparation and in vitro evaluation of pDNA-CaPi-...

on Yao xue xue bao = Acta pharmac... February 2013

PLGA nanoparticles of different surface properties...

on International Journal of Pharm... Jan 01, 2008

[Preparation of lectin-conjugated PLGA nanoparticl...

on Yao xue xue bao = Acta pharmac... May 2007

Preparation and evaluation of lectin-conjugated PL...

on Journal of Controlled Release Dec 01, 2006
More articles like this..